JPS57192435A - Modified polypeptide - Google Patents

Modified polypeptide

Info

Publication number
JPS57192435A
JPS57192435A JP56077153A JP7715381A JPS57192435A JP S57192435 A JPS57192435 A JP S57192435A JP 56077153 A JP56077153 A JP 56077153A JP 7715381 A JP7715381 A JP 7715381A JP S57192435 A JPS57192435 A JP S57192435A
Authority
JP
Japan
Prior art keywords
polypeptide
group
arom
physiological activity
modified polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56077153A
Other languages
Japanese (ja)
Inventor
Keiji Yukimatsu
Katsumi Hirose
Tsuneo Unuma
Keiko Tokunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP56077153A priority Critical patent/JPS57192435A/en
Publication of JPS57192435A publication Critical patent/JPS57192435A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PURPOSE: To provide a chemically, modified polypeptide in which antigenicity is eliminated while retaining the physiological activity of polypeptide at a high level, by subjecting amino groups in the molecule of polypeptide with a group contg. a specified polyethylene glycol residue.
CONSTITUTION: Part or the whle of amino groups in the molecule of polypeptide such as uricase, arginase or insulin is substituted with a group of formulaI (wherein R1 is F, Cl, OH or a group which does not react with the polypeptide; the group of formula II is a polyethylene glycol residue having a number- average MW of 5,000W15,000; R2 is alkyl, an arom. group, alkylcarbonyl, arom. carbonyl, alkylaminocarbonyl, arom. amino carbonyl) to produce a modified polypeptide which is an enzyme having a physiological activity effective in the treatment of patients and in which antigenicity is lowered or completely eliminated while retaining highly the physiological activity of the polypeptide.
COPYRIGHT: (C)1982,JPO&Japio
JP56077153A 1981-05-20 1981-05-20 Modified polypeptide Pending JPS57192435A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56077153A JPS57192435A (en) 1981-05-20 1981-05-20 Modified polypeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56077153A JPS57192435A (en) 1981-05-20 1981-05-20 Modified polypeptide

Publications (1)

Publication Number Publication Date
JPS57192435A true JPS57192435A (en) 1982-11-26

Family

ID=13625838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56077153A Pending JPS57192435A (en) 1981-05-20 1981-05-20 Modified polypeptide

Country Status (1)

Country Link
JP (1) JPS57192435A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPH01316400A (en) * 1988-03-31 1989-12-21 Kyowa Hakko Kogyo Co Ltd Modified polypeptide
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
JPH04217693A (en) * 1990-10-23 1992-08-07 Fuji Photo Film Co Ltd Peptide-containing polyethylene glycol derivative and its use
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO2002043772A3 (en) * 2000-11-30 2003-07-31 Shearwater Corp Water-soluble polymer conjugates of triazine derivatives
US6956027B2 (en) 1994-10-12 2005-10-18 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7090835B2 (en) 1994-10-12 2006-08-15 Amgen, Inc. N-terminally chemically modified protein compositions and methods
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
CZ303751B6 (en) * 1998-08-06 2013-04-24 Mountain View Pharmaceuticals, Inc. Uricase pharmaceutical composition, medicament, use and process for preparing thereof
US8921064B2 (en) 1998-08-06 2014-12-30 Mountain View Pharmaceuticals, Inc. Method for purifying urate oxidase tetramers and octamers
US9926538B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119082A (en) * 1978-03-08 1979-09-14 Mihama Hisaharu Modified asparagenase deactivated antibody property thereof and production
JPS5599189A (en) * 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119082A (en) * 1978-03-08 1979-09-14 Mihama Hisaharu Modified asparagenase deactivated antibody property thereof and production
JPS5599189A (en) * 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPH01316400A (en) * 1988-03-31 1989-12-21 Kyowa Hakko Kogyo Co Ltd Modified polypeptide
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5824778A (en) * 1988-12-22 1998-10-20 Kirin-Amgen, Inc. Chemically-modified G-CSF
JPH04217693A (en) * 1990-10-23 1992-08-07 Fuji Photo Film Co Ltd Peptide-containing polyethylene glycol derivative and its use
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US6956027B2 (en) 1994-10-12 2005-10-18 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7090835B2 (en) 1994-10-12 2006-08-15 Amgen, Inc. N-terminally chemically modified protein compositions and methods
US7662933B2 (en) 1994-10-12 2010-02-16 Amgen Inc. N-terminally chemically modified protein compositions and methods
US8258262B2 (en) 1994-10-12 2012-09-04 Amgen Inc. N-terminally chemically modified protein compositions and methods
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8067553B2 (en) 1998-08-06 2011-11-29 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
CZ303751B6 (en) * 1998-08-06 2013-04-24 Mountain View Pharmaceuticals, Inc. Uricase pharmaceutical composition, medicament, use and process for preparing thereof
US8618267B2 (en) 1998-08-06 2013-12-31 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8921064B2 (en) 1998-08-06 2014-12-30 Mountain View Pharmaceuticals, Inc. Method for purifying urate oxidase tetramers and octamers
WO2002043772A3 (en) * 2000-11-30 2003-07-31 Shearwater Corp Water-soluble polymer conjugates of triazine derivatives
US9926538B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US9926537B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11982670B2 (en) 2009-06-25 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Similar Documents

Publication Publication Date Title
JPS57192435A (en) Modified polypeptide
MY108496A (en) Hypoglycemic thiazolidine diones.
DE122005000002I1 (en) Use of venlafaxine or an aryloxy-propanamine derivative for the manufacture of a medicament for the treatment of incontinence.
GR1002802B (en) Cosmetic compositions and skin treatment compositions
BG103780A (en) Antitussive compositions
JPS5283846A (en) Heterocyclic compounds
NZ263740A (en) Ionene polymers as anthelmintics
ATE141802T1 (en) ILLUDIN ANALOGUES USED AS ANTI-TUMOR AGENT
MY131053A (en) 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
ATE108658T1 (en) USE OF TETRACYCLINE IN THE MANUFACTURE OF A MEDICATION FOR REDUCING EYE PRESSURE.
JPS53130752A (en) Aqueous silicone emulsion composition
JPS56148165A (en) Brushless motor
JPS5626962A (en) Coating composition
MD950010A (en) Composition for removing or deactivation of toxic components from blood and other extracellular body liquids and methol for prepations theref
JPS57165310A (en) First solution for permanent wave
JPS5665825A (en) Remedy for peptic ulcer
NZ217281A (en) Phenyl ether derivatives and pharmaceutical compositions
JPS5526881A (en) Semisynthesis of insulin
IE791946L (en) Treatment of wood
Catsaras Bacteriological aspect of bovine enterotoxemia.
UA28769A (en) Method of treatment of the skin radiation damages
JPS545991A (en) Thiadiazine derivatives, process for their preparation and their insecticides and miticides
JPS5699420A (en) Immune reactivator
JPS53144570A (en) 1-osoindolinone derivatives and agriculture and horticulture containing the same as active constituents
JPS5427590A (en) Preparation of thiadiazines